This very recent article is interesting:
https://www.theguardian.com/society/2023/apr/18/cancer-survivors-heightened-risk-heart-cardiovascular-disease?CMP=share_btn_tw
....with the detail published here: https://heart.bmj.com/content/early/2023/03/21/heartjnl-2022-321888
The researchers state that...
'...People who survive cancer may be at heightened risk of cardiovascular disease in subsequent years...'
Nothing new there, but I've described it as interesting because the researchers go further by suggesting what might be done about it:
“It may help to inform strategies for how some cancer survivors need to be monitored long-term, especially in situations where they have been discharged from cancer follow-up to the care of their GPs.”
In other words, they just seem to be accept cardiotoxicity as a regrettable, but inevitable, side effect for which an at-source solution just cannot even be contemplated; that the best to aim for is 'monitoring'.
That is why Zantrene has the potential to be considered a 'platform drug'.
Industry news, page-1261
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3015 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 4018 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |